Baxter International Inc (BAX)
UndervaluedFundamental
41
मूल्य
$23.70
मार्केट कैप
$12.14B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
ICU Medical sells IV solutions, infusion pumps and administration sets to the same US hospital pharmacies and supply contracts that Baxter's Medical Products & Therapies segment depends on.
BD competes head-on with Baxter for hospital infusion contracts with its Alaris smart pumps, IV sets and injectable drug delivery lines.
Stryker is the closest rival to Baxter's Hillrom business for smart hospital beds, patient monitoring and operating-room equipment bought by the same acute-care hospitals.
The German family-owned group offers the same sterile IV fluids, infusion pumps and parenteral nutrition range, and is Baxter's main rival for European hospital tenders.
Fresenius Kabi competes with Baxter both in IV fluids and parenteral nutrition and in specialty injectable generics sold to hospital pharmacies.
बैलेंस शीट और तरलता
राजस्व
$11.47B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-1.06B
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$332M
कुल इक्विटी
$6.13B
कुल देनदारियाँ
$13.95B
Current Ratio
1.95
Interest Coverage
0.93
Debt/EBITDA
0.31
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$64.96
वर्तमान मूल्य
$23.70
Margin of Safety
+63.5%
Fair Value सीमा
$42.22 - $87.69
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-15.6%
P/B Ratio
2.00
P/FCF
36.58
Gross Margin
30.1%
ROIC
-1.3%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-1.3%
WACC
8.3%
ROIC − WACC
-9.6 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (10)
- Gross Margin 30.1%
- P/B Ratio 2.00
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Earnings Surprise avg 15.7%
- Share Dilution 0.1%
- Piotroski F-Score 6/9
फेल (13)
- EPS shows upward trend
- Price CAGR -6.03%
- ROIC -1.3%
- P/FCF 36.58
- Operating Margin -2.4%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -16.6%
- Revenue Growth 5Y -0.8%
- Analyst Consensus 25% Buy
- Net Margin Trend -9.3% vs -1.4%
अनुपलब्ध (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर संख्या स्थिर है
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Andrew P. Hider | CEO, President, Interim Group President of Medical Products & Therapies and Director | 48 |
| Mr. David S. Rosenbloom | Executive VP & General Counsel | 65 |
| Ms. Maria Soriano | Group President of Infusion Therapies & Platforms | - |
| Ms. Anita A. Zielinski | Interim CFO, Senior VP, Chief Accounting Officer & Controller | 52 |
| Mr. Charles Patel | Senior VP & Chief Information Officer | 55 |
| Mr. Kevin Moran | Vice President & Head of Investor Relations | - |
| Ms. Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | - |
| Ms. Cynthia Carlisle | Executive VP & Chief Human Resources Officer | 50 |
| Mr. James W. Borzi | Executive VP & Chief Supply Chain Officer | 62 |
| Mr. Steven P. Wallace | President of Advanced Surgery & Commercial Excellence | 45 |
Audit जोखिम
3
बोर्ड जोखिम
2
मुआवजा जोखिम
9
शेयरधारक अधिकार जोखिम
2
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-12
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-07-30
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-08-19
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for BAX, sourced from Markets Gazette.